37% premium to date of strategic review, 8% discount to last close Equates to '24e-'26e EV/ARR of 4.
We raise adj. EBITA by 2-1-0% on '24e-'26e Adj. EBITA expected to grow 12% y-o-y in H2'24e 10-8x EBI...
We cut '24e-'26e sales by 7-10% Sominis divestment weighs on est.
Strong y-o-y growth: EEs +18%, SCs +36%, sales +22% EBIT margin 23% (25%), ~33% adjusted for FX effe...
-4% organisk tillväxt kompenseras av Thebalux-förvärvet Med höga jämförelsetal och fortsatt svår mar...
Rec. PTP -6% vs ABGSCe Sector-low LTV leaves room to grow Limited revisions, all eyes on CMD in 3w ...
- Q1e: sales +41% y-o-y, ~10% EBIT margin (SDR now consolidated) - Raising '24e EPS by 22% on huge u...
- Geographical diversity gives resilience - UK grew 6% org.
Redeye provides a research update following Lipum’s clinical progress, recent rights issue, and revi...
Efter att rekordordern som togs i det förra kvartalet levererats har Aixia ingått flertalet nya och ...
Calliditas confirms that the OLE (Open Label Extension study) treatment response is consistent with ...
Redeye leaves a comment following the yesterday’s press release of the preliminary outcome of Lipum’...
Scanfil’s Q1 results were expected to be soft relative to the comparison period but still came in so...
Innofactor’s Q1 was in line with expectations. We continued to expect modest growth in sales and EBI...
Emission avslutad Diamyd meddelade under föregående vecka utfallet av sin företrädesemission.
Redeye expected higher sales in the quarter. Particularly from Coating Services where revenues are t...
Organic growth of 79%, +34pp above ABGSCe Paying users 6% above ABGSCe Likely positive cons.
Adj. EBIT SEK 160m, 7% vs. ABGSC, 2% vs. cons No material changes to estimates expected Conference c...
Redeye comments on Carasent’s Q1 2024 report and its announcement of revised financial targets.
Strong growth, only slightly below our high expectations -4.
